her-2 pulsed dendritic cells
Vaccineexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00902044)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous her2-specific t cells
- her-2 pulsed dendritic cells
- her-2 pulsed dendritic cell vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05504707 | Phase 1 | Aug 11, 2022 | University of South Florida |
| NCT02473653 | N/A | Jun 1, 2015 | University of Pennsylvania |
| NCT02336984 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | University of South Florida |
| NCT02063724 | Phase 1 | Jan 1, 2014 | University of Pennsylvania, University of South Florida |
| NCT02061423 | Phase 1 | Jan 1, 2014 | University of South Florida |
| NCT00902044 | Phase 1 | Jul 1, 2009 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT02061332 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2009 | University of Pennsylvania |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of South Florida | Academic/Hospital | 4 | 4 | 2 | 2014 |
| University of Pennsylvania | Academic/Hospital | 3 | 2 | 3 | 2009 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1